43670 Federal Register / Vol. 86, No. 151 / Tuesday, August 10, 2021 / Notices 

Title 5, U.S.C., section 4314 (c) (4), 

which requires that members of 

performance review boards be 

appointed in a manner to ensure 

consistency, stability, and objectivity in 

performance appraisals and requires 

that notice of the appointment of an 

individual to serve as a member be 

published in the Federal Register. 

The following persons will serve on 

the NIH Performance Review Board, 

which oversees the evaluation of 

performance appraisals of NIH Senior 

Executive Service (SES) members: 

Alfred Johnson, Chair 

Courtney Billet 

Michael Gottesman 

Darla Hayes 

Michael Lauer 

Kathleen Stephan 

Lawrence Tabak 

Dated: August 2, 2021. 

Lawrence A. Tabak, 

Principal Deputy Director, National Institutes 

of Health. 

[FR Doc. 2021–17039 Filed 8–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Multi-Domain 

Amphipathic Helical Peptide for Use as 

A Human Therapeutic in Patients With 

Atherosclerotic Cardiovascular 

Disease, Including Patients 

Undergoing Cardiovascular Surgery 

Who Are at risk of Acute Kidney Injury 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Heart, Lung, and 

Blood Institute, an institute of the 

National Institutes of Health, 

Department of Health and Human 

Services, is contemplating the grant of 

an exclusive patent license to Phyxius 

Therapeutics, Inc., a start-up company 

incorporated as a C corporation under 

the laws of the state of Delaware, to 

practice the inventions covered by the 

patent estate listed in the 

SUPPLEMENTARY INFORMATION section of 

this notice. This is a first notice 

intended to apprise the public of a 

change in prospective licensee of the 

subject intellectual property rights in 

the stated field of use. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Heart, Lung, 

and Blood Institute on or before August 

25, 2021 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an exclusive patent license should be 

directed to: Michael Davis, J.D., Ph.D., 

Senior Technology Transfer Manager, 31 

Center Drive Room 4A29, MSC2479, 

Bethesda, MD 20892–2479, phone 

number 301–451–9032, or 

michael.davis4@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

NIH REF No. Title Patent Application No. Filing Date Issued Patent 

No. Issue Date 

E–114–2004–0– 

US–01.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.60/619,392 10/15/04 ........................ ........................

E–114–2004–0– 

PCT–02.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.PCT/US2005/ 10/14/05 ........................ ........................

E–114–2004–0– 

AU–03.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.2005295640 10/14/05 2005295640 11/10/11 

E–114–2004–0– 

CA–04.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.2584048 10/14/05 2584048 08/09/16 

E–114–2004–0– 

EP–05.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.05815961.7 10/14/05 1812474 05/26/10 

E–114–2004–0– 

JP–06.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.2007–536912 10/14/05 5,091,679 09/21/12 

E–114–2004–0– 

US–07.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.11/577,259 04/13/07 7,572,771 08/11/09 

E–114–2004–0– 

US–08.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.12/497,443 07/02/09 8,071,746 12/06/11 

E–114–2004–0– 

US–09.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.12/766,761 04/23/10 8,148,323 04/03/12 

E–114–2004–0– 

CH–11.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.05815961.7 10/14/05 1812474 05/26/10 

E–114–2004–0– 

DE–12.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.05815961.7 10/14/05 1812474 05/26/10 

E–114–2004–0– 

ES–13.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.05815961.7 10/14/05 1812474 05/26/10 

E–114–2004–0– 

FR–14.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.05815961.7 10/14/05 1812474 05/26/10 

E–114–2004–0– 

GB–15.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.05815961.7 10/14/05 1812474 05/26/10 

E–114–2004–0– 

IT–16.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.05815961.7 10/14/05 1812474 05/26/10 

E–114–2004–0– 

US–17.

Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.13/407,132 02/28/12 8,835,378 09/16/14 

All U.S. and foreign patents and 

applications claiming priority to any 

member of the above. 

The patent rights in these inventions 

have been assigned or exclusively 

licensed to the Government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and in fields 

of use that may be limited to use as a 

human therapeutic in patients with 

atherosclerotic cardiovascular disease 

(ASCVD), including patients undergoing 

cardiovascular surgery who are at risk of 

acute kidney injury. 

The patents listed above cover an 

invention directed to peptides or 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 151 / Tuesday, August 10, 2021 / Notices 43671 

peptide analogs with multiple 

amphipathic alpha helical domains that 

promote lipid efflux from cells via an 

ABCA1-dependent pathway. This 

invention is also directed to methods of 

identifying non-cytotoxic peptides that 

promote ABCA1-dependent lipid efflux 

from cells, and to methods of using 

multi-domain amphipathic alpha helical 

peptides or peptide analogs to treat or 

inhibit dyslipidemic disorders. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing. The prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Heart, Lung, and Blood Institute 

receives written evidence and argument 

that establishes that the grant of the 

license would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this notice will be presumed 

to contain business confidential 

information and any release of 

information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Bruce D. Goldstein, 

Director, Office of Technology Transfer and 

Development, National Heart, Lung, and 

Blood Institute. 

[FR Doc. 2021–17011 Filed 8–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

[Docket Number—DHS–2021–0037] 

Agency Information Collection 

Activities: Office of the Immigration 

Detention Ombudsman Intake Form 

AGENCY: Department of Homeland 

Security (DHS). 

ACTION: 60-Day Notice and request for 

comments; Office of the Immigration 

Detention Ombudsman Intake Form, 

1601–0030, Extension without change. 

SUMMARY: The Department of Homeland 

Security, will submit the following 

Information Collection Request (ICR) to 

the Office of Management and Budget 

(OMB) for review and clearance in 

accordance with the Paperwork 

Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted until October 12, 2021. 

ADDRESSES: You may submit comments, 

identified by docket number Docket # 

DHS–2021–0037 at: 

Æ Federal rulemaking Portal: http://

www.regulations.gov. Please follow the 

instructions for submitting comments. 

Instructions: All submissions received 

must include the agency name and 

docket number Docket # DHS–2021– 

0037. All comments received will be 

posted without change to http://

www.regulations.gov, including any 

personal information provided. 

Docket: For access to the docket to 

read background documents or 

comments received, go to http://

www.regulations.gov. 

SUPPLEMENTARY INFORMATION: The 

Department of Homeland Security’s 

(DHS) Office of the Immigration 

Detention Ombudsman (OIDO) is an 

independent office tasked with 

resolving individual complaints from or 

about individuals in immigration 

detention regarding the potential 

violation of immigration detention 

standards or other potential misconduct. 

OIDO was established by Congress (Sec. 

106 of the Consolidated Appropriations 

Act, 2020, Pub. L. 116–93). Its intake 

form is intended for use by individuals 

wishing to submit a complaint to OIDO. 

Information collected will provide the 

office with details about the allegations 

the submitter seeks to have OIDO 

address. 

The information collected on this 

form will allow OIDO to identify: (1) 

The individual submitting the 

complaint and their contact 

information; (2) the detained individual 

who is the subject of the complaint; (3) 

the government-owned or contracted 

facility where the individual is or was 

detained and for how long; and (4) 

relevant details about the complaint. All 

of this information will be used by 

OIDO to investigate, resolve, and if 

appropriate, provide redress. 

The use of this form is the most 

efficient means for collecting and 

processing the required data. Initially, 

collection will be via a paper form, 

which may be obtained from OIDO staff 

conducting routine visits in detention 

facilities. The form will also be available 

for download from the OIDO website. 

The PDF form will be able to be 

completed online, printed out, and 

submitted to OIDO by email, mail, or 

fax, or handed to a staff member in a 

detention facility. 

After approval of the form described 

in this supporting statement, an 

electronic version will be developed so 

that submitters may complete and file 

via the OIDO website. The paper version 

will continue to be available; it will be 

noted on the form that using the paper 

method may result in processing delays 

for OIDO to complete data entry. 

This information collection does not 

have an impact on small businesses or 

other small entities. 

If this information is not collected, 

OIDO will not be able to accomplish its 

Congressional mandate to provide 

assistance to individuals who may be 

affected by misconduct, excessive force, 

or other violations of law or detention 

standards. 

The assurance of confidentiality 

provided to the respondents for this 

information collection is based on the 

forthcoming Privacy Impact Assessment 

for the Immigration Detention 

Ombudsman Case Management System 

(ID–CMS) (Summer 2021). Additionally, 

the information collected is covered by 

DHS/ALL–020 Department of Homeland 

Security Internal Affairs, April 28, 2014, 

79 FR 23361 and DHS/ALL–025 Law 

Enforcement Authority in Support of 

the Protection of Property Owned, 

Occupied, or Secured by the 

Department of Homeland Security 

System of Records, June 14, 2017, 82 FR 

27274. 

This information collection was 

constructed in compliance with 

regulations and authorities under the 

purview of the DHS Privacy Office, DHS 

OCIO, DHS Records Management, and 

OMB regulations regarding data 

collection, use, sharing, storage, 

information security, and retrieval of 

information. 

There are no changes to the 

information being collected and there is 

no change to the estimated burden 

associated with this collection. 

The Office of Management and Budget 

is particularly interested in comments 

which: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 


jbell on DSKJLSW7X2PROD with NOTICES